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Down syndrome (DS) is one of the most frequent genetic abnormalities characterized by multiple pathological phenotypes.
Indeed, currently life expectancy and quality of life for DS patients have improved, although with increasing age pathological
dysfunctions are exacerbated and intellectual disability may lead to the development of Alzheimer’s type dementia (AD). The
neuropathology of DS is complex and includes the development of AD bymiddle age, altered free radical metabolism, and impaired
mitochondrial function, both of which contribute to neuronal degeneration. Understanding the molecular basis that drives the
development of AD is an intense field of research. Our laboratories are interested in understanding the role of oxidative stress as
link between DS and AD. This review examines the current literature that showed oxidative damage in DS by identifying putative
molecular pathways that play a central role in the neurodegenerative processes. In addition, considering the role of mitochondrial
dysfunction in neurodegenerative phenomena, results demonstrating the involvement of impaired mitochondria in DS pathology
could contribute a direct link between normal aging and development of AD-like dementia in DS patients.
1. Down Syndrome
Down syndrome (DS) is the most common genetic cause
of mental retardation that arises from the triplication of
the entire, or even part of chromosome 21 (trisomy21).
Although the genetic alterations are responsible of the major
clinical presentations of the disease such as craniofacial
abnormalities, small brain size, accelerated aging, and cog-
nitive defects, additional environmental factors seem to play
an important role in determining the severity of multiple
phenotypes. Genetic instability due to trisomy leads to the
development of two types of phenotypes: (1) those present in
every DS individual and (2) those that occur only in a subset
of DS individuals. In addition, for any given phenotype
there is considerable variability in expression that further
results in a complex, “not-predictable” set of clinical signs
[1]. For example, the extent of cognitive impairment in
the DS population presents with a wide range of diversity.
This wide variability may be explained, at least in part, by
the “gene dosage hypothesis,” which states that some of the
genes encoded on Chr21 are dosage sensitive—that is, three
copies result in phenotypic effects—and contribute to the
phenotypes of DS [2, 3]. This proposed scenario is further
complicated by the fact that the abnormal expression of
trisomic genes also affects disomic genes as well, which, in
turn, are in part responsible of some clinical manifestations
and ultimately results in as assembly of different DS pheno-
types [4]. Thus, according to “the amplified developmental
instability hypothesis”, the most important cause of the array
of phenotypic features does not actually involve exclusively
specific genes on Chr21 but rather elevated activity of sets of
genes, regardless of their identity, which lead to a decrease in
genetic stability or homeostasis [5] An interesting example
of this effect is represented by the findings that newborns
and children with DS are predisposed to a range of blood
disorders, which include acute lymphoblastic leukaemia
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and acute megakaryocytic leukaemia (AMKL). In addition
to trisomy 21, fetal haemopoietic progenitors acquire N-
terminal truncating mutations in the key megakaryocyte-
erythroid transcription factor GATA1 [6].
Improvements in quality of life of individuals with
DS have resulted from improvements in medical care,
identification and treatment of psychiatric disorders (such
as depression, disruptive behavior disorders, and autism),
and early educational interventions with support in typical
educational settings [7, 8]. Also, largely owing to advances in
medical care and attitude changes, the median age of death
in this population has increased to 49 years, and the life
expectancy of a 1-year-old person with Down syndrome is
more than 60 years and is likely to improve [8].
Considering that DS patients presently have an improved
life expectancy and quality of life, the comprehension
of degenerative phenomena related to accelerated aging
and neurodegeneration has received much attention from
researchers. In fact, a link between the DS phenotype and
an increased risk of the development of AD has now been
firmly established [9]. The prevalence of dementia among
DS patients is 8% in the age range 35–49, 55% in the
age range 50–59, and 75% above the age of 60 years,
but AD neuropathology is present in all of the cases by
the age of 40 [10]. AD like dementia in DS population
is characterized by the presence of senile plaques (SPs)
and neurofibrillary tangles (NFTs) and by cholinergic and
serotonergic reduction [11, 12]. However, although most DS
patients have plaques early in life and even in the fetus,
it is only very later on that they may develop AD. Thus,
identification of common pathways together with specific
differences of the neurodegenerative process occurring both
in DS and AD currently represents an intense field of
research. Among proposed hypothesis, oxidative stress is
receiving much attention and may be considered a bridge
between DS and AD.
2. Oxidative Stress (OS) in DS
Increasing number of studies have recently shown that
OS occurs in DS pathogenesis and progression due to a
deregulation of gene/protein expression associated with the
trisomy characteristic of DS [13]. Increased production of
ROS is also accompanied by mitochondrial dysfunction,
which occurs in DS cells as early as from embryonic life
[14]. Although oxidative stress implications in DS phenotype
have been demonstrated [10, 11, 15–17], a direct cause-and-
effect relationship between the accumulation of oxidatively
mediated damage and clinical manifestation of DS is not
yet strongly established. Growing evidence supports the
occurrence of chronic oxidative injury in the brain that could
imply a risk factor for subsequent neurodegeneration in aged
DS patients [4, 18, 19]. Increased conditions of oxidative
stress are caused by the overexpression of some of the genes
encoded by Chr21 (Figure 1). Among these, one of the most
relevant as a potential OS inducer is copper-zinc superoxide
dismutase (SOD1). SOD1 is thought to have a major role
in the first line of antioxidant defense by catalyzing the
dismutation of O2
•− to molecular oxygen (O2) and H2O2,
which can be converted by catalase (CAT) and by (selenium-
containing) glutathione peroxidase (GPX) to water [20].
The triplication of Chr21, on which the SOD-1 gene is
localized, leads to an imbalance in the ratio of SOD-1 to
CAT and GPX, resulting in the accumulation of H2O2 [10].
Interestingly, all DS tissues, in addition to the brain, display
an altered SOD-1/GPX activity ratio [21]. SOD-1 was found
at levels approximately 50% higher than normal in a variety
of DS cells and tissues, including erythrocytes, B and T
lymphocytes, and fibroblasts. Indeed, the erythrocytes of DS
children, adolescents, and adults exhibited systemic increases
in SOD-1, SOD-1/GPX, or the SOD-1/(GPX + CAT) activity
ratio. In addition, a decreased expression of peroxiredoxin
2 was detected in DS fetal brain which may contribute to
enhanced susceptibility of DS neurons to free radical attack
[22].
A crucial role of SOD-1 is further demonstrated by the
study of Shin et al. which reported that transgenic mouse
strains overexpressing wild-type human SOD1 (Tg-SOD1)
showed to have mitochondrial swelling, vacuolization, or
learning and memory deficits [23]. Mitochondrial ATP syn-
thase alpha/beta chain and elongation factor Tu were aber-
rant in Tg-SOD1, while antioxidant proteins were found to
be unchanged. Derangement of neuronal and mitochondrial
proteins may indicate synaptosomal and neuronal loss in
Tg-SOD1 hippocampus, already reported in morphological
terms, and could help to understanding brain deficits in DS.
Consonant with the above-cited studies, Busciglio and
Yankner [14] reported that neurons of DS patients exhibited
a sharp increase in intracellular ROS which is also accom-
panied by elevated levels of lipid peroxidation. In addition,
a proteomics study from Gulesserian et al. [24] showed that
oxidative stress in fetal DS did not result from overexpression
of SOD-1 protein but appeared to be the consequence of
low levels of antioxidant enzymes involved in removal of
hydrogen peroxide, such as glutathione transferases and
thioredoxin peroxidases.
Interestingly, elevated levels of OS could also be caused
by increased release of amyloid beta-peptide (Aβ). Many
studies demonstrated that both Aβ(1-40/42) are able to
induce OS [25–31]. Thus, the overexpression of the amyloid
precursor protein (APP) gene, which is also encoded by
Chr21, could explain in DS patients the overproduction of
Aβ peptide, the major protein in SPs. Indeed, postmortem
studies on DS brain evidenced accumulation of Aβ(1-42)
peptide, a characteristic hallmark of AD pathology, which
correlate with age [32]. Mehta et al. [33] found that Aβ(1-
42) and Aβ(1-40) levels were higher in DS plasma than
controls. The ratio of Aβ42/Aβ40 was lower in DS than in
controls and a significant negative correlation between age
and Aβ40 in DS and controls were observed, and between
age and Aβ42 levels in DS but not in controls. Recently,
a paper from the same group demonstrated that among
adults with DS, decreasing levels of plasma Aβ42, a decline
in the Aβ42/Aβ40 ratio, or increasing levels of Aβ40 may be
sensitive indicators of conversion to AD, possibly reflecting
compartmentalization of Aβ peptides in the brain [34].
However, recent studies from Anandatheerthavarada et al.
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Figure 1: Oxidative stress and down syndrome. Increased conditions of oxidative stress are caused by the overexpression of some of the
genes encoded by Chr21. Among these, amyloid precursor protein (APP), copper-zinc superoxide dismutase (SOD1), and beta secretase
(BACE2) can directly or indirectly lead to OS.
[35] indicated that also full length APP itself may have
deleterious effects, particularly targeting mitochondria. The
authors proposed that under increased APP expression, a
progressive accumulation of transmembrane-arrested APP
caused perturbation of mitochondrial function, which in
turn resulted in impairment of energy metabolism.
Moreover, mice overexpressing wild type human APP
display cognitive defects and neuronal pathology similar
to AD; these mice do not show significant Aβ deposition
in the hippocampus [36]. In these mice, hAPP processing
was basically nonamyloidogenic, while increased levels of
phosphorylated tau in the hippocampus were observed.
These findings support the notion that trisomy of APP may
promote mitochondrial dysfunction in DS independent of
aberrant Aβ deposition.
Related to APP metabolism, another gene encoded by
Chr21 is the β-site APP-cleaving 2 enzyme (BACE2). BACE
is homologous to BACE1, a β-secretase involved in the
amyloidogenic pathway of APP proteolysis, and thus it has
been hypothesized that the co-overexpression of both genes
could contribute to Alzheimer’s like neuropathology present
in DS. However, co-overexpression of BACE2 and APP did
not increase amyloid-β peptide concentration in brain of Tg
mice. These results suggest that the in vivo effects of APP are
not exacerbated by BACE2 co-overexpression but may have
some protective effects in specific behavioral and cognitive
domains in transgenic mice [37].
By mapping Chr21, another candidate gene that may
be involved in OS is the enzyme carbonyl reductase (CBR).
Carbonyls, which are cytotoxic metabolic intermediates,
are detoxified by either oxidation catalyzed by aldehyde
dehydrogenase (ALDH) or by reduction to their correspond-
ing alcohols by carbonyl reductase (CBR) and/or alcohol
dehydrogenase (ADH). Protein levels of both enzymes were
found to be increased in several brain regions of both DS
and AD patients because of enzyme induction by elevated
carbonyls in DS and AD [38]. Further, carbonyl reductase is
an oxidatively modified protein in brain of subjects arguably
with the earliest form of AD,mild cognitive impairment [39].
There is evidence of a link between 1-carbon/trans
sulfuration (1C-TS) metabolism and DS. There are at least
six genes encoding enzymes important for 1C-TS metab-
olism located on human Chr21, including the gene for
cystathionine beta synthase (CBS) [40]. CBS catalyzes the
condensation of serine and homocysteine to form cystathio-
nine. It plays a critical role in linking the folate cycle and
the methionine cycle and in regulating homocysteine levels
[41]. In addition, CBS can convert cysteine to hydrogen
sulfide, which researchers are beginning to recognize as
an important neuromodulator in the brain [42]. There is
evidence that CBS protein levels and enzyme activity are
increased in persons with DS [43]. Elevated CBS activity can
lower homocysteine levels, which in turn perturb the balance
of 1C-TS metabolism and lead to elevated—perhaps toxic—
levels of hydrogen sulfide. These metabolic alterations might
play a role in the cognitive disability seen in DS [44, 45].
Accordingly, CBS is considered a risk factor for AD [46].
Another player in the complex C1-TS metabolism is
also the trifunctional enzyme complex glycinamide ribonu-
cleotide synthase-aminoimidazole ribonucleotide synthase-
glycinamide formyl transferase (GARS-AIRS-GART), which
catalyzes certain steps of de novo purine synthesis [47].
GART is aberrantly regulated and overexpressed in DS
individuals and may be involved in the phenotype of DS
[47]. Accumulation of uric acid, the end product of purine
metabolism, is another feature of DS and there are some
hypotheses about the pathogenetic mechanism leading to its
increase [48]. Hyperuricemia has an interesting relationship
with oxidative stress since it represents an important free
radical scavenger and ROS themselves could influence its
increase.
Chr21 also maps the gene for S100β, an astroglial-
derived Ca2+-binding protein having neurotrophic role on
neurons and glial cells. S100β is responsible to start up a
gliotic reaction by the release of proinflammatory mediators,
including nitric oxide and cytokines from microglia and
astrocytes, which are, in turn, deleterious for neurons [49].
Interestingly, proinflammatory effect of S100β seems not
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to be restricted into the brain. Macrophages play a pivotal
role in inflammatory diseases, occurring both in the brain
and in the periphery. An aberrant S100β production has
been observed in DS and AD [50]. It has been shown that
S100β stimulates both NO production and iNOS protein
transcription and expression in rat peritoneal macrophages
[49].
Elevated OS has been demonstrated in peripheral and
CNS specimens of DS patients and models thereof [14].
Increased levels of TBARS, total protein carbonyls, and
advanced glycation endproducts (AGEs) in the cortex from
DS fetal brain compared with controls were reported [51]
and a marked accumulation of 8-hydroxy-2-deoxyguanosine
(8OHdG), oxidized proteins and nitrotyrosine, in the cyto-
plasm of cerebral neurons in DS was found [52]. Elevated
levels of isoprostane 8,12-iso-iPF2α (iPF2α), a specific
marker of lipid peroxidation, have been measured in urine
samples from adults with DS [25]. In addition, levels of
AGEs, dityrosine, H2O2, and nitrite/nitrate were found to
be significantly increased in urine samples of DS compared
with age-matched controls [53]. These markers of oxidative
damage were considered more consistent compared with
8-OHG, 15-F(2t)-IsoP, and TBARS which gave contrasting
results. However, additional studies on large population are
needed to confirm the reproducibility of these results.
The majority of OS data have been obtained by the
analysis of animal models of the disease, including Ts65Dn
mice and Ts1Cje mice. The Ts65Dn mouse carries a small
chromosome derived primarily from mouse chromosome
16, causing dosage imbalance for approximately half of
human chromosome 21 orthologs. These mice have cere-
bellar pathology with direct parallels to DS [54]. The
Ts1Cje mouse, containing a translocated chromosome 16,
is at dosage imbalance for 67% of the genes triplicated
in Ts65Dn [55]. Ts1Cje mice do not express the SOD1
gene and show some DS-related abnormalities such as
craniofacial alterations [56] and spatial learning deficits [57],
but different from Ts65Dn mice.
Ishihara et al. [27] reported increased level of ROS and
mitochondrial dysfunction in primary cultured astrocytes
and neurons from Ts1Cje transgenic mice, confirming that
the “gene-dosage” hypothesis is sufficient to explain, at
least, the major part, of OS-induced intracellular damage
observed in this animal model of DS. The authors also
identified by redox proteomics approach the putative target
proteins that were modified by lipid peroxidation-derived
products [27]. ATP synthase mitochondrial F1 complex
b subunit, α-enolase, and triosephosphate isomerase 1
were identified as proteins modified by 3-hydroperoxy-
9Z,11E-octadecadienoic acid (13-HPODE). Neurofilament
light polypeptide, internexin neuronal intermediate fila-
ment α, neuron specific enolase, peroxiredoxin 6, phos-
phoglycerate kinase 1, and triosephosphate isomerase were
shown to be HNE-modified proteins. Thus, dysfunction of
these proteins as a consequence of oxidative damage may
affect ATP production, the neuronal cytoskeleton system,
and antioxidant network function. Interestingly, previous
redox proteomics studies from our laboratory previously
found some of these proteins modified by hydroxynonenal,
a reactive product of lipid peroxidation, in AD and MCI
brain [39, 58, 59], suggesting that these brain proteins might
contribute to cognitive dysfunction and neurodegenerative
processes occurring in DS. These findings point out that DS
and AD share common pathways of neurodegeneration that
need to be further elucidated.
In an effort to better understand the role of oxidative
stress we have analyzed the amniotic fluid (AF) from women
carrying DS pregnancy compared with that from women
carrying healthy fetuses. While the majority of the studies
have been performed on Down fetal brains or DS mouse
model, few data are available on AF, which is a more reliable
index of the physiological condition of the fetus. In analogy
with CSF, which is considered “a window into the brain”, AF
could be used for the identification of disease biomarkers to
be coupled with current genetic screening. Thus, AF provides
both physical and biochemical support for the developing
fetus. Its composition is complex and includes fetal and
maternal proteins, amino acids, carbohydrates, hormones,
lipids, and electrolytes. Since AF is in direct contact with
multiple organs of the fetus, AF contains high concentrations
of proteins that are directly secreted from the fetus [60]. Not
surprisingly, recent technological advances in proteomics
have been actively utilized to investigate AF, in order to
better understand its complex biological function and to
discover disease-specific biomarkers for fetal aneuploidies
and pregnancy-related complications. Once an abnormal
proteomic profile is identified, it has to be compared with
healthy closely matched controls, allowing for a disease-
specific biomarker to be identified [61, 62].
Thus, we have evaluated a set of oxidative stress bio-
markers in amniotic fluid from women carrying DS fetuses,
and we found increased levels of oxidative stress, as indexed
by increased protein oxidation, lipid peroxidation, reduction
of GSH and Trx levels, and induction of the heat shock
protein (HSP) response. By a redox proteomics approach,
we have identified selective proteins that showed increased
oxidation in DS AF compared with that from mothers
carrying healthy fetuses. The identified proteins are involved
in iron homeostasis (ceruloplasmin and transferin), lipid
metabolism (Zinc-alpha2-glycoprotein, retinol binding pro-
tein 4 and Apolipoprotein A1), and inflammation (Comple-
ment C9, Alpha-1B-glycoprotein, Collagen alpha-1V chain)
with critical relevance in the clinical outcome of DS [63].
As previously mentioned, another important player in
the oxidative stress hypothesis of neurodegeneration is Aβ
peptide. Brain from DS subjects show consistent Aβ deposi-
tion and neurofibrillary tangle formation [64] that correlate
with of age. Although plaque deposition is a very early event
in DS patients, even in fetal development, it is only very later
on that they may develop AD [65]. In fact, increased signs of
dementia in DS after the age of 50 years appeared many years
later the first signs of significant insoluble Aβ accumulation
or plaque deposition and also after the first signs of
neurofibrillary tangle pathology [66]. Thus, other factors,
which may not directly link Aβ metabolism and tangles
formation, have to be involved to cause consistent neuronal
dysfunction and cognitive decline. Synaptic dysfunction may
be a consequence of APP overexpression or increased Aβ
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[67]. Neuroinflammation [68], endosomal dysfunction [69],
and oxidative damage [52] may play a crucial role in DS as
well as in AD pathology [66].
Recent studies by our laboratory [17] were performed
to establish an association between brain oxidative dam-
age and Aβ neuropathology as a function of age in DS
patients. Preliminary results showed that DS brains with
neuropathological hallmarks of AD have more oxidative,
but not nitrosative, stress than those with DS but without
significant AD pathology, as compared with similarly aged-
matched non-DS controls. Further studies are needed to
better understand aging-related phenomena in DS, which
from one side contribute to development of AD but also
paradoxically result in AD neuropathology but without
dementia.
The neuropathology of DS is complex and occurs with
a wide variability. The characteristic hallmarks of neurode-
generative process are altered free radical metabolism and
impaired mitochondrial function which both contribute to
development of AD by middle age [70–72]. However, recent
studies reported a quite surprising trend of oxidative stress
damage in DS. While increased OS is detectable as early
as during pregnancy [73] and increases over age in young
DS, adults with DS do not show a significant increased
oxidative damage to DNA [74]. These data could appear
contradictory with other findings supporting the correlation
of increased oxidative damage with increasing age. One
of the reasons could be related to the samples analyzed,
that is, peripheral lymphocytes, which indicate a cell-type
with specific functionality and which could be able to
activate compensatory mechanisms as the brain does not.
In addition, different markers of oxidative stress do not
always correlate with each other, because the ability of the
cell to repair differently a “specific” damage in addition to
different susceptibility of lipids, proteins, and nucleic acid to
accumulates oxidative damage.
It seems likely that young DS experienced a sort of
chronic oxidative stress and those “surviving” cells become
more resistant by activating defense mechanisms that coun-
teract increasing oxidative stress conditions over the lifespan
[74]. This is reasonable by considering that newborn DS have
to challenge with high levels of ROS that are responsible of
the pathogenesis of many of the pathological manifestations.
In contrast, this “experience” of OS promotes the survival
of more resistant cellular phenotypes that show several
dysfunctions (Figure 2). This hypothesis is further supported
by studies from Head et al. [65], who showed by PET that
compensatory increases in metabolic rate and activation of
plasticity mechanisms in vulnerable brain regions in DS
occurred prior to the development of dementia. The same
genes, including APP, DYRK1A, SOD1, and RCAN1, which
once overexpressed are responsible of impaired neuronal
growth and synapse maintenance on the contrary may also
promote the activation of compensatory mechanisms during
aging [65].
For example, secreted forms of AβPP, in addition to be
neurotoxic, can also function as neuroprotective factors [75]
and possible cell adhesion molecules [76] and also play a role
in cell signaling [77]. Interaction of AβPP with multiple
protein networks might result in activation of complex
compensatory responses. RCAN1 (regulator of calcineurin
1) has recently been shown to act synergistically with
DYRK1A to impair the function of NFAT transcription
factors which are involved in cell development. RCAN1
is highly expressed in neurons and overexpressed in DS
brain [78]. Possible additional roles for RCAN1 include
modulation of the chromosome 21 gene SOD1 [79] and
playing a critical role in mitochondrial function [80]. It
seems likely that some trisomic genes may interact with
each other and are responsible of learning and memory
deficit during development, but with increasing age their
interaction may become beneficial and possibly protective
[60]. The molecular mechanisms which drive dysfunction
versus protection need to be extensively investigated. Based
on these considerations, enhancing or supporting compen-
satory mechanisms in aging individuals with DS may be
beneficial as suggested by intervention studies in animal
models.
3. Mitochondrial Dysfunction in DS
Several reports have demonstrated that mitochondrial im-
pairment plays a central role on neurodegeneration [16].
The first abnormalities of mitochondrial function (abnormal
shape, reduced levels of microtubules, etc.) was observed
in cultured cerebellar neurons from trisomy 16 (Ts16) mice
[81]. Previous findings demonstrated deficient functionality
of mitochondrial enzymes, including monoamine oxidase,
cytochrome oxidase, and isocitrate dehydrogenase [82].
Numerous studies have demonstrated that the accumula-
tion of mitochondrial DNA (mtDNA) mutations is a major
contributor to degenerative diseases and human ageing
[83]. Studies from several groups suggested that mtDNA
mutations have a role in the pathogenesis of DS [71, 84,
85]. Apart from helping to explain free radical damage and
development of AD, the presence of mtDNAmutations could
explain the association of DS with premature ageing and
diabetes [86]. Mutations in mtDNA may bring about an
increase in the generation of free radicals and reduce ATP
levels. This, in turn, could affect the synaptonemal complex
and chromosome segregation, also alter recombination and
so lead to aneuploidy.
Druzhyna et al. [87] demonstrated not only an increase
of mtDNA oxidative damage but also a reduced functionality
of specific repair systems in fibroblasts from DS patients.
Increased oxidative damage was a consequence of increased
superoxide formation that was demonstrated in Ts16 neu-
rons compared to control neurons. This condition persisted
also in the presence of rotenone, a mitochondrial respiratory
chain complex I inhibitor, which was able to block O2
•−
production in diploid neurons, but not in Ts16 neurons.
This different behavior between Ts16 neurons and diploid
neurons also was evident when cells were treated with car-
bonyl cyanide p-trifluoromethoxyphenylhydrazone, used to
uncouple mitochondrial oxidative phosphorylation, which
caused irreversible deficiency in the energy metabolism in
Ts16 neurons, but not in diploid control neurons. Thus, an
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Figure 2: Putative adaptation to OS in down syndrome. OS occurs early in DS pathogenesis and progression. Accumulation of oxidative
damage leads to severe phenotypes while the induction of compensatory mechanisms in response to chronic OS could result in “adaptation”
and could contribute to improve the life span of DS subjects.
increased O2
•− basal generation in Ts16 neurons results from
deficient complex I coupled with an impaired mitochondrial
energy metabolism that ultimately leads to neuronal cell
death [88]. A selective impairment of complex I activity
was demonstrated in isolated cortex mitochondria from Ts16
mice by administration of its normal substrates, malate, and
glutamate, but not with the Complex II substrate succinate
[89]. Accordingly, a very recent paper by Valenti et al.
[90] reported a selective deficit in the catalytic efficiency of
Complex I in DS-HSFs (Down’s syndrome human fetal skin
fibroblasts). The Complex I deficit was associated with a
decrease in cAMP-dependent phosphorylation of the 18 kDa
subunit of the complex, due to a decrease in PKA (protein
kinase A) activity related to reduced basal levels of cAMP.
Furthermore, the authors measured a 3-fold increase in
cellular levels of ROS, in particular O2
•−, mainly produced
by DS-HSF mitochondria. This effect was prevented by
dibutyryl-cAMP, a membrane-permeable cAMP analogue,
suggesting its involvement in ROS production.
H2O2 production and calcium uptake did not differ
significantly in the Ts16 mitochondria, while a decrease in
pyruvate dehydrogenase levels was detected, similar to the
pattern found in Parkinson’s disease [91].
Further details on mitochondrial functionality were
underscored by a study by Conti et al. [13]. The authors
analyzed the expression profile of several genes located
on Chr21 using oligonucleotide microarrays in hearts of
human DS fetuses compared with normal fetuses. The
authors concluded that dosage-dependent upregulation of
Chr21 genes causes dysregulation of the genes responsible
for mitochondrial function and for the extracellular matrix
organization in the fetal heart of trisomic subjects [13].
Direct evidence for an in vivo alteration of mito-
chondrial function in blood cells from DS patients was
reported by Roat et al. [92], who found an increased
loss of ΔΨ(m), underlying the presence of an increasing
susceptibility of these organelles to damaging agents. As
noted above, mitochondrial function is also regulated by
the methyl status due to the presence on Chr21 of the
gens for specific CBS, which participates in recycling of
methionine/homocysteine in the methyl cycle sequence of
reactions. In fact, methylation is a necessary event in
mitochondria and relies on the availability and uptake of the
methyl donor S-adenosylmethionine. Indeed mitochondrial
dysfunctions have been widely described in DS, but they have
never been correlated to a possible mitochondrial methyl
unbalance. Infantino et al. [93] recently showed that the
mitochondrial levels of S-adenosylmethionine were reduced
in DS compared to control cells consistent with a methyl
imbalance on mitochondria functionality.
4. Concluding Remarks
Within the context of the reported findings discussed above,
we hypothesize that trisomy affects gene/protein expres-
sion that results in increased OS conditions and impaired
mitochondrial function. These alterations occur early in DS
as demonstrated by studies performed on fetal brain and
amniotic fluid from DS pregnancy and play an important
role in neurodegeneration.
Several studies suggested different mechanistic causes for
the changes in redox state in contributing to early neural
pathological changes in DS brain. OS conditions arise not
only from overexpression of SOD1 but also as a consequence
of low levels of reducing agents and antioxidant enzymes.
Redox imbalance is further affected by overproduction of Aβ,
which accumulates into plaques across the lifespan in DS as
well as in AD. Aβ toxicity has been shown to be a major
effector of neuronal loss and cognitive dysfunctions observed
both in DS and in AD and contributes to exacerbate oxidative
damage into the brain. In fact, OS is a crucial factor because
it affects multiple pathways related to cell growth/death, gene
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expression, and protein function, among many others. It is
now well accepted that OS contribute to neurodegeneration,
but in the case of DS and AD, genetic similarities, due to
the fact that some of the genes responsible for familial form
of AD are encoded by Chr21, provide an interesting field of
research for the comprehension of many yet unsolved issues.
Based on this notion, it is possible that using antiox-
idant nutrients to scavenge oxygen-derived free radicals
may modulate some of the complications of DS. A very
recent paper by Lott et al. [94] demonstrated that a 2-
year randomized, double-blind, placebo-controlled trial with
daily oral antioxidant supplementation (900 IU of alpha-
tocopherol, 200mg of ascorbic acid, and 600mg of alpha-
lipoic acid) was effective, safe, and tolerable for individuals
with DS and dementia. However, individuals receiving the
antioxidant supplement showed neither an improvement in
cognitive functioning nor a stabilization of cognitive decline
compared with control group.
These data are in contrast with those obtained by
Lockrow et al. [95], who treated Ts65Dn mice with a long-
term antioxidant supplementation. Supplementation with
vitamin E effectively reduced the levels of ROS in the
adult Ts65Dn brain. Also, Ts65Dn mice receiving vitamin
E exhibited improved performance on a spatial working
memory task and showed an attenuation of cholinergic
neuron pathology in the basal forebrain.
This discrepancy likely results from the “biological gap”
between human and animal studies. Though transgenic mice
are a useful model to study the molecular basis of a disease
and test the efficacy of drug treatment, they do not show all
the features of human disease. In particular, when testing
the protective effects of antioxidants, supplementation has
to be initiated before persistent oxidative damage occurs.
For example, many individuals with AD most likely have
significant AD pathology by the time of diagnosis. This
phenomenon, reasonably, is one of the major limits of
clinical trials that should be taken into account, such that
antioxidants should be administered as putative modulators
of disease at the very early stage of the disease.
Although limits of antioxidant therapies exist, an intrigu-
ing prospective could be offered by the comprehension of
putative compensatory mechanisms which are activated even
in the presence of genetic instability in the DS population
that could play a role in explaining the wide variability of
phenotypes. In fact, although overexpression of several genes
on Chr21, including APP, DYRK1A, SOD1, and RCAN1, lead
to impaired neuronal growth and synapse maintenance, at
the same time the same genes may also induce an adaption
through the action of compensatory pathways during aging.
DS may represent an informative model of prodromal AD;
thus, promising results may be available by the analysis of
DS brain or brain from DS-relevant transgenic mice. Such
studies are ongoing in our laboratories.
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